Trial Profile
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs BIIB-095 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Biogen
- 18 Mar 2022 Results evaluating concentration-Qtc relationship of Biib095 presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 15 May 2019 Status changed from recruiting to completed.